Eiger BioPharmaceuticals, Inc. (EIGRQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Eiger BioPharmaceuticals, Inc. (EIGRQ) trades at $8.50 with AI Score 54/100 (Grade B). Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing therapies for hepatitis delta virus (HDV) and other serious diseases. Market cap: $12.59M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for EIGRQ: EIGRQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EIGRQ against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
EIGRQ: 3/6 perspectives are bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Eiger BioPharmaceuticals, Inc. (EIGRQ) Healthcare & Pipeline Overview
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company specializing in therapies for hepatitis delta virus (HDV) and rare diseases like Hutchinson-Gilford progeria syndrome. Their lead product, Zokinvy, addresses progeria, while Lonafarnib targets HDV. The company is currently navigating Chapter 11 reorganization.
What Is the Investment Thesis for EIGRQ?
Eiger BioPharmaceuticals, Inc. presents a high-risk, high-reward investment opportunity. The company's focus on rare diseases and HDV, a significant unmet medical need, offers potential for substantial growth if Lonafarnib gains regulatory approval and achieves commercial success. However, the recent Chapter 11 filing introduces significant uncertainty and risk. The company's gross margin of 95.1% indicates strong pricing power for its existing product, Zokinvy. Investors should closely monitor the bankruptcy proceedings, clinical trial outcomes for Lonafarnib and Peginterferon Lambda, and the company's ability to secure financing and restructure its operations. The company's beta of 2.78 suggests high volatility.
Based on FMP financials and quantitative analysis
EIGRQ Key Highlights
- Market Cap of $12.59M reflects the company's distressed valuation following the Chapter 11 filing.
- Gross Margin of 95.1% indicates strong pricing power for Zokinvy, the company's commercialized product.
- P/E Ratio of -0.17 indicates the company is currently unprofitable.
- Profit Margin of -475.3% highlights the significant losses the company is incurring.
- Chapter 11 filing on April 1, 2024, introduces substantial risk and uncertainty for investors.
Who Are EIGRQ's Competitors?
EIGRQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRPOF Ceapro Inc. | $0.17 | -13.04% | $13.31M | 46 |
| LVCLY Living Cell Technologies Limited | $0.03 | +24.39% | $11.39M | 45 |
| MGCLF MGC Pharmaceuticals Limited | $0.27 | +2.88% | $12.11M | 46 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EIGRQ's Key Strengths?
- Approved product (Zokinvy) generating revenue.
- Promising pipeline of product candidates targeting unmet medical needs.
- Expertise in developing therapies for rare diseases.
- Strong gross margin.
What Are EIGRQ's Weaknesses?
- Chapter 11 bankruptcy filing.
- High operating losses and negative profit margin.
- Dependence on regulatory approval for pipeline products.
- Limited financial resources.
What Could Drive EIGRQ Stock Higher?
- Potential regulatory approval of Lonafarnib for HDV.
- Progress in Chapter 11 bankruptcy proceedings.
- Clinical trial results for Peginterferon Lambda.
- Development of Avexitide for hyperinsulinism.
What Are the Key Risks for EIGRQ?
- Financial-distress signal — its Altman Z-Score of -24.29 sits in the distress zone (elevated bankruptcy risk).
- Chapter 11 bankruptcy proceedings and potential liquidation.
- Failure to obtain regulatory approval for pipeline products.
- Competition from other companies developing therapies for similar diseases.
- Inability to secure financing to fund operations.
- Limited liquidity and price volatility on the OTC market.
What Are the Growth Opportunities for EIGRQ?
- Lonafarnib Approval for HDV: Lonafarnib represents a significant growth opportunity for Eiger. HDV affects millions globally, and an approved therapy could generate substantial revenue. The Phase 3 clinical trials have been completed, and regulatory approval is the next step. The timeline for approval depends on the FDA review process, but potential approval could occur within the next 12-18 months, pending the resolution of the Chapter 11 reorganization.
- Peginterferon Lambda Development: Peginterferon Lambda is in clinical development for HDV and has also been investigated for COVID-19. The potential market for HDV treatment is substantial, and success in this area could drive significant growth. Further clinical trial results and regulatory decisions will determine the timeline and market potential.
- Avexitide for Hyperinsulinism: Avexitide, currently in Phase II development for congenital hyperinsulinism and post-bariatric hypoglycemia, addresses a niche market with limited treatment options. Successful clinical trials and regulatory approval could provide a valuable revenue stream. The timeline for commercialization depends on the progress of clinical trials and regulatory review.
- Expansion of Zokinvy Market: Zokinvy, approved for Hutchinson-Gilford progeria syndrome, can be expanded to new geographies and patient populations. While progeria is a rare disease, increasing awareness and diagnosis can drive growth. The company can also explore new formulations or indications for Zokinvy to further expand its market potential.
- Strategic Partnerships and Acquisitions: Eiger can pursue strategic partnerships or acquisitions to expand its product pipeline and market reach. Collaborations with other biotechnology companies or research institutions can accelerate the development of new therapies and provide access to new technologies. The company's Chapter 11 reorganization may impact its ability to pursue such opportunities in the near term.
What Opportunities Does EIGRQ Have?
- Regulatory approval of Lonafarnib for HDV.
- Expansion of Zokinvy market to new geographies and patient populations.
- Strategic partnerships and collaborations to expand pipeline.
- Development of new therapies for other rare diseases.
What Threats Does EIGRQ Face?
- Failure to obtain regulatory approval for pipeline products.
- Competition from other companies developing therapies for similar diseases.
- Uncertainty related to Chapter 11 bankruptcy proceedings.
- Inability to secure financing to fund operations.
What Are EIGRQ's Competitive Advantages?
- Patents and intellectual property protection for its therapies.
- Regulatory exclusivity for approved products, such as Zokinvy.
- Specialized expertise in developing therapies for rare diseases.
- Established relationships with key opinion leaders and patient advocacy groups.
What Does EIGRQ Do?
Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for serious diseases with unmet medical needs. The company's lead product, Zokinvy, is approved for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Additionally, Eiger is developing Lonafarnib, an orally available farnesylation inhibitor, for the treatment of Hepatitis Delta Virus (HDV) infection, a disease with no approved therapies until recently. Peginterferon Lambda (lambda) is another product candidate in clinical development for HDV and has also been investigated for mild and moderate COVID-19. Avexitide is in Phase II development for congenital hyperinsulinism and post-bariatric hypoglycemia. Founded to address rare and orphan diseases, Eiger has evolved into a commercial-stage company with a focus on HDV and other serious conditions. Headquartered in Palo Alto, California, Eiger BioPharmaceuticals filed for Chapter 11 reorganization on April 1, 2024.
What Products and Services Does EIGRQ Offer?
- Develop and commercialize therapies for hepatitis delta virus (HDV).
- Offer Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome.
- Develop Lonafarnib, an orally available farnesylation inhibitor, for HDV infection.
- Develop Peginterferon Lambda (lambda) for HDV and COVID-19.
- Develop Avexitide for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia.
- Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
How Does EIGRQ Make Money?
- Develop and obtain regulatory approval for pharmaceutical products.
- Manufacture and market approved products directly or through partnerships.
- Generate revenue through the sale of pharmaceutical products.
- Invest in research and development to discover and develop new therapies.
What Industry Does EIGRQ Operate In?
Eiger BioPharmaceuticals operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The company focuses on niche markets such as rare diseases and HDV, where there are limited treatment options and significant unmet medical needs. The competitive landscape includes companies developing therapies for viral infections and rare genetic disorders. The biotechnology industry is driven by innovation and regulatory approvals, with market trends favoring targeted therapies and personalized medicine.
Who Are EIGRQ's Key Customers?
- Patients with Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies.
- Patients with Hepatitis Delta Virus (HDV) infection.
- Patients with congenital hyperinsulinism and post-bariatric hypoglycemia.
- Healthcare providers who prescribe and administer Eiger's therapies.
Company Profile
Eiger BioPharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Palo Alto, US. The company is led by CEO David Apelian. EIGRQ has traded publicly since 2014.
Eiger BioPharmaceuticals, Inc. (EIGRQ) Valuation Context
Valued at $12.59M, EIGRQ is classified as a micro-cap stock. Relative to its peer group, EIGRQ's quantitative score of 54/100 is roughly in line with the peer average of 59/100.
F-Score 4/9Financial Health
Eiger BioPharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -24.29 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Eiger BioPharmaceuticals, Inc. revenue of about $34.4M for fiscal 2026, with EPS near $-2.70.
EIGRQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Eiger's pipeline still holds potential despite recent setbacks. They're not out of the game yet. Think Biogen after its Alzheimer's drug approval rollercoaster – sentiment can shift fast.
- The social buzz, though mixed, shows people are still watching Eiger closely. No one talks about dead stocks.
- Insider buying, even in small amounts, suggests some believe in a turnaround. It's a vote of confidence, however small.
- The 'underdog' narrative could attract speculative interest. Remember GameStop? Never underestimate the power of the crowd.
Bear Case
- The bankruptcy filing is a major red flag. It signals severe financial distress. Think Lehman Brothers – it's hard to recover from that kind of hit.
- Community sentiment is largely negative, reflecting the bankruptcy. This creates a self-fulfilling prophecy as investors lose faith.
- Market perception is overwhelmingly bearish given the company's financial state. No one wants to catch a falling knife.
- The risk of complete wipeout is very real. Shareholders are last in line during bankruptcy proceedings. It's a gamble, not an investment.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
EIGRQ Latest News
No recent news available for EIGRQ.
EIGRQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EIGRQ.
Price Targets
Wall Street price target analysis for EIGRQ.
EIGRQ MoonshotScore
What does this score mean?
The MoonshotScore rates EIGRQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David Apelian
CEO
David Apelian serves as the CEO of Eiger BioPharmaceuticals, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on clinical development and commercialization. Prior to joining Eiger, he held leadership positions at various pharmaceutical companies, overseeing the development and launch of several successful products. His expertise spans multiple therapeutic areas, including infectious diseases and rare genetic disorders. He is responsible for managing 25 employees.
Track Record: Under David Apelian's leadership, Eiger BioPharmaceuticals has achieved key milestones, including the approval and commercialization of Zokinvy for Hutchinson-Gilford progeria syndrome. He has also overseen the advancement of Lonafarnib through Phase 3 clinical trials for HDV. The Chapter 11 filing occurred during his tenure, presenting a significant challenge for the company.
EIGRQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Eiger BioPharmaceuticals, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, are in financial distress, or have chosen not to comply with higher reporting standards. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to NYSE or NASDAQ-listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and disclosure requirements.
- Potential for low trading volume and price volatility.
- Increased risk of fraud or manipulation.
- Uncertainty related to the company's Chapter 11 bankruptcy proceedings.
- Difficulty in obtaining reliable financial information.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Review the company's business plan and growth strategy.
- Evaluate the company's competitive position and market opportunities.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Commercial-stage biopharmaceutical company with an approved product (Zokinvy).
- Focus on developing therapies for serious diseases with unmet medical needs.
- Experienced management team with a background in the biopharmaceutical industry.
- Completion of Phase 3 clinical trials for Lonafarnib.
- Listing on the OTC market, indicating some level of public trading.
Common Questions About EIGRQ (Healthcare)
What does Eiger BioPharmaceuticals, Inc. do?
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for serious diseases with unmet medical needs, particularly hepatitis delta virus (HDV) and rare diseases. The company's lead product, Zokinvy, is approved for the treatment of Hutchinson-Gilford progeria syndrome. Eiger is also developing Lonafarnib for HDV and other product candidates for congenital hyperinsulinism and post-bariatric hypoglycemia. The company operates by developing and seeking regulatory approval for its therapies, then commercializing them to address specific patient populations.
What are the main risks for EIGRQ?
The primary risk for Eiger BioPharmaceuticals, Inc. is the ongoing Chapter 11 bankruptcy proceedings, which could result in significant losses for shareholders or even liquidation of the company. Additional risks include the potential failure to obtain regulatory approval for pipeline products, competition from other companies developing therapies for similar diseases, and the company's limited financial resources. Investing in EIGRQ carries substantial risk due to its distressed financial situation and the inherent uncertainties of the biotechnology industry.
What are the key factors to evaluate for EIGRQ?
Eiger BioPharmaceuticals, Inc. (EIGRQ) holds an AI score of 54/100 (moderate). Not financial advice.
How frequently does EIGRQ data refresh on this page?
EIGRQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven EIGRQ's recent stock price performance?
Eiger BioPharmaceuticals, Inc. (EIGRQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Approved product (Zokinvy) generating revenue. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EIGRQ overvalued or undervalued right now?
Valuing Eiger BioPharmaceuticals, Inc. (EIGRQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying EIGRQ?
Before investing in Eiger BioPharmaceuticals, Inc. (EIGRQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding EIGRQ to a portfolio?
Key strength of Eiger BioPharmaceuticals, Inc. (EIGRQ): Approved product (Zokinvy) generating revenue. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- The company's Chapter 11 bankruptcy proceedings introduce significant uncertainty.